See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Longwood Fund is a Boston-based venture capital firm dedicated to creating and investing in science-based companies that develop novel solutions for important medical problems. The firm acts as company co-founders, company builders, and value-add investors — partnering with world-class entrepreneurs, scientists, and academic innovators to identify groundbreaking discoveries and translate them into important new medicines. Longwood partners typically serve as Co-Founding CEO, CBO, or President, taking an active operational role in building each company from inception. With more than $650 million in AUM across six funds, the firm focuses on early-stage biotech across oncology, neuroscience, rare/genetic diseases, immunology, and gene therapy, co-founding at least half of its portfolio companies and supporting them through early financing rounds brought by top-tier syndicate partners.
Notable quotes
“This fund exceeded our target raise and will allow us to continue focusing on investing in Longwood-founded companies as well as early financing rounds brought to us by our network of top-tier syndicate partners. We are excited to continue working with leading academic researchers and entrepreneurs on cutting-edge technology to create world-class life science companies that will develop the next generation of drugs for patients.”
“The current disconnect between abundant scientific innovation and limited available capital creates a unique opportunity to build and grow the early-stage programs that will generate tomorrow's therapies.”
“We continue to employ a consistent strategy, with a fund size optimized for a focused portfolio where we co-found and invest in companies with strong syndicate partners.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Coultreon Biopharma | Series A | $125m | 2026-04-28 |
| Sidewinder Therapeutics | Series B | $137m | 2026-04-08 |
| Newleos Therapeutics | Series A | $94m | 2025-02-13 |
| XyloCor Therapeutics | Series B | $68m | 2025-01-07 |
| Progentos Therapeutics | Series A | $65m | 2024-05-20 |
| Immunitas Therapeutics | Series A | $39m | 2019-11-21 |
| TScan Therapeutics | Series A | $48m | 2019-01-01 |
| Be Biopharma | Seed | — | — |
| GRAIL | Series A | — | — |
| Vor Biopharma | Series A | — | — |
Frequent co-investors
Fit check
Is Longwood Fund a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit